Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome

Neurology

Volumn 76, Issue 3, 2011, Pages 236-241

  Lehky, T J ^a   Iwamoto, F M ^b   Kreisl, T N ^b   Floeter, M K ^a   Fine, H A ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; ETIRACETAM; TANDUTINIB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DIPLOPIA; DISTAL LIMB WEAKNESS; DRUG WITHDRAWAL; DYSPHAGIA; EDEMA; ELECTROMYOGRAM; FACE WEAKNESS; GLIOBLASTOMA; HUMAN; LIMB WEAKNESS; MALE; MOTOR UNIT POTENTIAL; MUSCLE WEAKNESS; MYASTHENIA; MYASTHENIC LIKE SYNDROME; NECK WEAKNESS; NERVE STIMULATION; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR JUNCTION TOXICITY; NEUROPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REPETITIVE NERVE STIMULATION; SEIZURE; TREATMENT DURATION; VASOGENIC EDEMA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG ADMINISTRATION SCHEDULE; ELECTROMYOGRAPHY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASES; NEUROMUSCULAR JUNCTION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; SYNDROME;

EID: 78751619064     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182074a69     Document Type: Article

References (13)

1. Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma 2007;8(suppl 1):S24-S34.
2. Cheng Y, Paz K. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs 2008;11:46-56.
3. Ranza E, Mazzini G, Facoetti A, Nano R. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol 2010;96:349-57.
4. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.
5. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111: 1287-1295.
6. DeAngelo DJ, Stone RM, Heaney ML, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacoki-netics, and pharmacodynamics. Blood 2006;108:3674-3681.
7. Liveson JA, Ma DM. Laboratory Reference for Clinical Neurophysiology. Philadelphia: FA Davis; 1992.
8. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinote-can at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
9. Farrugia ME, Robson MD, Clover L, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006; 129:1481-1492.
10. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/ muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002;25:4-16.
11. Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by ima-tinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53.
12. Zhao Y, Haginoya K, Iinuma K. Strong immunoreactivity of platelet-derived growth factor and its receptor at human and mouse neuromuscular junctions. Tohoku J Exp Med 1999;189:239-244.
13. Penn AS, Low BW, Jaffe IA, et al. Drug-induced autoimmune myasthenia gravis. Ann NY Acad Sci 1998;841: 433-449.